Tag: CELMoD
-
Bristol Myers Squibb’s Zenbexus Cuts Progression or Death Risk by 51% in Phase 3 Trial
Bristol Myers Squibb’s Zenbexus regimen reduced the risk of progression or death by 51% and extended median progression-free survival to 42 months in Phase 3 EXCALIBER-RRMM.
-
Bristol Myers Squibb (BMS) Wins FDA Approval for the First CELMoD Therapy in Multiple Myeloma
The FDA granted accelerated approval to Bristol Myers Squibb’s Zenbexus (iberdomide) as part of a three-drug regimen for previously treated multiple myeloma, marking the first approval of a CELMoD therapy.